Trial Profile
A Phase I, randomised, double blind, placebo-controlled, dose-escalating study of the safety, tolerability and pharmacokinetics of single and repeat doses and food effect of AK-119 administered orally to healthy volunteers
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2019
Price :
$35
*
At a glance
- Drugs AK 119 Akaal Pharma (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Akaal Pharma
- 16 Jul 2019 Status changed from not yet recruiting to recruiting.
- 31 Oct 2018 New trial record